Ovarian Epithelial Cancer Recurrent Clinical Trial
Official title:
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase I-II Clinical Trial
Patients with first recurrent resistance ovarian cancer and disease progression with peritoneal carcinomatosis will undergo PIPAC procedure. The primary end point is to determine the clinical benefit rate (CBR) of a pressurized intraperitoneal aerosol chemotherapy with a combination of cisplatin and doxorubicin.
This study aims to investigate the therapeutic efficacy of PIPAC using cisplatin and doxorubicin in women with first recurrent resistance ovarian cancer and disease progression with peritoneal carcinomatosis. The primary objective of this study is to determine the Clinical Benefit Rate (CBR) according to RECIST/GCOG criteria after three cycles of PIPAC with PIPAC cisplatin and doxorubicin ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01899599 -
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01715168 -
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT02394015 -
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
|
||
| Completed |
NCT01588964 -
IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02026921 -
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02260544 -
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
|
Phase 1 | |
| Completed |
NCT01735071 -
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01611766 -
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
|
Phase 3 | |
| Completed |
NCT02014337 -
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01376752 -
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
|
Phase 3 |